ICAD INC. - COMMON STO

iCAD features Solis Mammography in upcoming “ProFound Insights, ProFound Impact” webinar

08 дек 2022 08:00:02 Источник Nasdaq GlobeNewswire

iCAD and Google Health Ink Strategic Development and Commercialization Agreement

28 ноя 2022 08:00:01 Источник Nasdaq GlobeNewswire

Positive New Research Presented at RSNA 2022 Reaffirms iCAD’s Breast AI Suite Improves Radiologists’ Performance and Breast Cancer Detection

21 ноя 2022 08:00:33 Источник Nasdaq GlobeNewswire

iCAD to Participate in the 13th Annual Craig-Hallum Alpha Select Conference

15 ноя 2022 16:13:15 Источник Nasdaq GlobeNewswire

iCAD to Present at HLTH 2022 With Google

14 ноя 2022 08:00:02 Источник Nasdaq GlobeNewswire

iCAD Reports Financial Results for Third Quarter Ended September 30, 2022

10 ноя 2022 16:03:15 Источник Nasdaq GlobeNewswire

iCAD to Join Forces with Radiology Partners, the Nation’s Largest Radiology Practice

10 ноя 2022 16:01:00 Источник Nasdaq GlobeNewswire

iCAD to Report Third Quarter 2022 Financial Results on November 10, 2022

27 окт 2022 08:40:03 Источник Nasdaq GlobeNewswire

iCAD and Solis Mammography Ink Deal to Collaborate on Use of AI to Evaluate Risk of Cardiovascular Disease

11 окт 2022 08:00:01 Источник Nasdaq GlobeNewswire

iCAD To Participate in The Lake Street Capital Markets 6th Annual Best Ideas Growth (BIG6) Conference on September 14, 2022

07 сен 2022 08:00:02 Источник Nasdaq GlobeNewswire

iCAD Customers in the U.S. and Europe Increasingly Adopting Company’s Full Suite of Breast AI Technologies via Subscription Model

29 авг 2022 08:00:00 Источник Nasdaq GlobeNewswire

iCAD Reports Financial Results For Second Quarter 2022

10 авг 2022 16:07:50 Источник Nasdaq GlobeNewswire

iCAD to Report Second Quarter 2022 Financial Results on August 10, 2022

27 июл 2022 08:00:01 Источник Nasdaq GlobeNewswire

iCAD Presents its Complete Suite of Breast Cancer AI Solutions at the European Congress of Radiology

13 июл 2022 08:00:01 Источник Nasdaq GlobeNewswire

ProFound AI Risk Real-World Case Studies to be featured in iCAD’s “ProFound Insights, ProFound Impact” Webinar Series

29 июн 2022 08:00:01 Источник Nasdaq GlobeNewswire

iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Highlight ProFound AI Risk

07 июн 2022 08:00:01 Источник Nasdaq GlobeNewswire

iCAD to Present at the JMP Securities Life Sciences Conference on June 15-16, 2022

06 июн 2022 08:08:21 Источник Nasdaq GlobeNewswire

iCAD Announces CFO Transition

25 май 2022 08:01:43 Источник Nasdaq GlobeNewswire

New Real-World Evidence Shows ProFound AI Improves Cancer Detection and Accuracy with Digital Breast Tomosynthesis, or 3D Mammography

18 май 2022 08:00:01 Источник Nasdaq GlobeNewswire

New Research Finds iCAD's ProFound AI Risk for Digital Breast Tomosynthesis is 2.4x More Accurate than Traditional Lifetime Risk Models

16 май 2022 08:00:02 Источник Nasdaq GlobeNewswire